Citations

Clear

2960 citation(s) found for "Kim, P".

CTIM-23. A PHASE II STUDY OF RETIFANLIMAB (PD-1 INHIBITOR) AND EPACADOSTAT (IDO1 INHIBITOR) IN COMBINATION WITH BEVACIZUMAB AND HYPOFRACTIONATED RADIOTHERAPY FOR RECURRENT GLIOBLASTOMA: NCT03532295
Butt, Abeer, Yu, Tao , Butt, Omar H. , Etter, Kelsey, Nehring, Leslie, Hissim, Deanna, McKean, Cole, Ansstas, George , Abraham, Christopher , Kizilbash, Sani H. , Johanns, Tanner M. , Ciorba, Matthew A. , Campian, Jian , Chheda, Milan G. , Kizilbash, Sani H , Luo, Jingqin , Etter, Kelsey, Hissim, Deanna C, McKean, Cole, Kim, Albert Sungsoo , Strowd, Roy E. , Huang, Jiayi

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii90-viii90

10.1093/neuonc/noae165.0356 Get It

Abstract INTRODUCTION Immunotherapy has not improved survival in recurrent GBM (rGBM). Indoleamine 2,3 dioxygenase 1 (IDO1), highly expressed in ~90% of patients with malignant glioma, is a rate-limiting enzyme that catabolizes tryptophan (Trp) into kynurenine (Kyn) and enables immune escape. METHODS We hypothesized combining therapies targeting immunosuppressive pathways with cytotoxic and antiangiogenic therapies would overcome tumor-related immunosuppression. This was an open-label Phase II study of two regimens: Arm A consisted of retifanlimab (anti-PD1, 500mg IV Q4W) + bevacizumab (10mg/kg IV Q2W) + HFRT (3.5Gy/day x 10) in patients with IDH1/2-WT rGBM. Regimen B added the IDO inhibitor, epacadostat (400mg po BID), initiated prior to HFRT. Key inclusion criteria included dexamethasone ≤ 4 mg/day. The primary endpoint was overall survival (OS) at 9 months (OS-9). 24 evaluable patients were required to detect an OS-9 of 60% with 80% power, compared to 38% in historical controls (bevacizumab alone) by 1-sided 1-sample log rank test at alpha=0.1. RESULTS We previously reported Arm A. Here, we present results from Arm B. 25 of the 27 patients enrolled to regimen B were evaluable: median age 58years (23-71); 28% female; 23% MGMT promotor methylated; median KPS 90 (70 - 100); a median of 6 cycles of epacadostat as of May 2024 (1 - 13). 18 of 25 died with a median follow up 9.23 months. Median PFS was 7.52 months (95%CI: 5.52-9.43). Median OS was 9.5 months (95%CI 8.08-11.96). Regimen B met its primary endpoint with OS-9 of 61.07% (95%CI: 38.23-77.65%). There were 5 possible immune-related grade 3+ toxicities to date (2 ALT/AST increase; 3 rash). CONCLUSIONS Retifanlimab, epacadostat, HFRT, and bevacizumab in rGBM is well-tolerated, with encouraging OS and PFS at the time of submission. Arm B met its primary endpoint. Further studies are warranted to identify biomarkers to predict long-term responders.
DDEL-01. ENGINEERING MRNA THERAPIES FOR BRAIN TUMORS
Yerneni, Saigopalakrishna S. , Strelkova-Petersen, Daria, Gallagher, Brendan R. , Kim, Julie Shin, McAllister‐Lucas, Linda M. , Pardi, Norbert , Azambuja, Juliana H. , Chaudhary, Namit , Zhao, Yongxin , Lucas, Peter C. , Weissman, Drew , Whitehead, Kathryn A.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii121-viii121

10.1093/neuonc/noae165.0468 Get It

Abstract Safe delivery of mRNA to the brain will revolutionize the treatment of brain tumors. While lipid nanoparticles (LNPs) are clinically most advanced non-viral delivery vehicles for therapeutic mRNA, LNP-mediated mRNA delivery to the brain remains challenging. We hypothesized that rationally designed LNPs based on extracellular vesicle mimicry would enable efficient delivery of RNA therapeutics to brain cells without undue toxicity. We engineered LNPs consisting of four components similar to the formulation used in the mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech): ionizable lipid, cholesterol, helper lipid and polyethylene glycol (PEG)-lipid. We screened ten classes of helper lipids based on lipids enriched in extracellular vesicles to engineer biomimetic LNPs and tested their GFP mRNA delivery efficacy in SIM-A9 mouse microglia cell line. Several unique LNP formulations with potent delivery efficacy (>90% cells transfected) and stable GFP expression kinetics (5 days) were identified. LNP formulations with high transfection efficacy were then tested in vivo for luciferase mRNA delivery via intrathecal injection in C57BL/6 mice. Luciferase expression in vivo confirmed widespread mRNA delivery in the brain. We then tested Cre recombinase mRNA delivery in Ai9 mouse to identify LNP-targeted cells via flow cytometry and histology. Flow cytometry and expansion microscopy confirmed Cre recombinase mRNA delivery to a variety of brain cells, including microglia (75-90%), neurons (31-40%), neural stem cells (39-62%), oligodendrocytes (70-90%), and astrocytes (44-76%). LNPs were further evaluated for Cas9 mRNA and CD81 sgRNA delivery in C57BL/6 mouse brains to assess brain-targeted gene editing. Sanger sequencing showed that CRISPR-Cas9 editing was successful in ~40% of cells in the mouse brain. In summary, we engineered extracellular vesicle-based LNP library that can deliver RNA therapeutics to a variety of brain cells in vivo. With further development, this technology could potentially enable genetic and epigenetic therapies targeting drivers of brain tumors.
The Feasibility and Usability of an Artificial Intelligence-Enabled Conversational Agent in Virtual Reality for Patients with Alcohol-Associated Cirrhosis: A Multi-Methods Study
Clark, Allistair , Mehra, Muskaan , Danovitch, Itai , Yang, Ju Dong , Vipani, Aarshi , Wang, Yun F. , Ayoub, Walid S. , Trivedi, Hirsh D. , Wu, Tiffany , Shah, Vijay H. , Liran, Omer , Clark, Allistair , Mehra, Muskaan , Spiegel, Brennan , Wu, Tiffany , Yeo, Yee Hui , Osilla, Karen Chan , Yang, Ju Dong , Kuo, Alexander , Kim, Hyunseok , Samaan, Jamil S. , Spiegel, Brennan

Mayo Clinic

Journal of Medical Extended Reality | November 11, 2024 | Volume: 1 | Issue: 1 | Pages: 257-270

10.1089/jmxr.2024.0033 | PMID 42558099 Get It

A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
DePalo, Danielle K. , Dugan, Michelle M. , Naqvi, Syeda Mahrukh Hussnain , Ollila, David W. , Hieken, Tina J. , Block, Matthew S. , Houdt, Winan J. van , Reijers, Sophie J. M. , Asher, Nethanel , Duncan, Zoey , Anderson, Matilda, Snow, Hayden , Held, Jenny M., Farma, Jeffrey M. , Vetto, John T. , Hui, Jane Yuet Ching , Kolbow, Madison , Saw, Robyn P.M. , Lo, Serigne , Long, Georgina V. , Karapetyan, Lilit , Akkooi, Alexander C. J. van , van Houdt, Winan J , Asher, Nethanel , Hui, Jane Yuet Ching , Kolbow, Madison , Lo, Serigne N , Thompson, John F , Zager, Jonathan S , Hieken, Tina J , Long, Georgina V , Wouters, Michel W.J.M. , Broman, Kristy K. , Gyorki, David E. , Held, Jenny, Thompson, John F. , Kim, Youngchul , Ny, Lars , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Cancer | November 10, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35636 | PMID 39522025 Get It

AbstractBackgroundIsolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in‐transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene laherparepvec [TVEC]) introduced several different management options. This study compares first‐line ILI/ILP, ICI, and TVEC.MethodsRetrospective review from 12 international institutions included patients treated from 1990 to 2022 with first‐line ILI/ILP, ICI, or TVEC for unresectable melanoma ITM.ResultsA total of 551 patients were treated, with ILI/ILP (n = 356), ICI (n = 125), and TVEC (n = 70) with median follow‐up of 5.5 years. Tumor burden was highest with ILI/ILP and lowest with TVEC (p = .002). Breslow thickness was lowest with TVEC (p = .007). TVEC was mostly used in stage IIIB disease versus IIIC for ILI/ILP and ICI (p = .01). Using ICI as the reference category, TVEC had the highest odds of a complete response (CR) (odds ratio, 1.96; p = .029) and a longer local progression‐free survival (PFS) (hazard ratio [HR], 0.40; p = .003). ILI/ILP had shorter local PFS (HR, 1.72; p = .012), PFS (HR, 1.79; p < .001), distant metastasis‐free survival (DMFS) (HR, 1.75; p = .014), overall survival (HR, 1.82; p = .009), and melanoma‐specific survival (HR, 2.29; p = .004). Stage IIIB disease had longer DMFS (HR, 0.24; p < .001) compared to IIIC/D.ConclusionsTVEC as first‐line therapy for unresectable melanoma ITM was associated with superior CR rates and local PFS. Notably, TVEC was used in patients with a lower Breslow thickness, disease stage, and tumor burden. Therefore, when compared to ILI/ILP and ICI, TVEC should be considered as first‐line therapy for unresectable stage IIIB melanoma ITM with minimal tumor burden and lower Breslow thickness.
The Fourth Annual Symposium of the Midwest Aging Consortium
Kim, Jinoh , Buffenstein, Rochelle , Vanegas, Natalia-Del Pilar , Agudelo-Garcia, Paula A., Rojas, Mauricio , Englund, Davis A. , Nunes, Allancer , Kohut, Marian L. , Kothadiya, Siddhant , Bardhan, Rizia , Camell, Christina D. , Sturmlechner, Ines , Lamming, Dudley W. , Leiser, Scott F. , Escorcia, Wilber , Gill, Matthew S. , Helfand, Stephen L., Korm, Sovannarith , Pehar, Mariana , Blaszkiewicz, Magdalena , McGregor, Eric R. , Stilgenbauer, Lukas , Taylor, Alicia , McNeill, Elizabeth M. , Sturmlechner, Ines , Lamming, Dudley W , Anderson, Rozalyn M , Bai, Hua , Englund, Davis A. , Bronikowski, Anne M. , Rosas, Lorena , Mora, Ana Lucia , LeBrasseur, Nathan K. , Robbins, Paul D. , Goronzy, Jörg J. , Yeh, Chung‐Yang , Huang, Shijiao , Taylor, Jackson R. , Gribble, Kristin E. , Townsend, Kristy L. , Anderson, Rozalyn M. , Sadagurski, Marianna , Stoeger, Thomas

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | November 5, 2024 | Volume: 79 | Issue: 11 | Pages: No page available

10.1093/gerona/glae236 | PMID 39498863 Get It

Abstract The Midwest Aging Consortium (MAC) has emerged as a critical collaborative initiative aimed at advancing our understanding of aging and developing strategies to combat the rising prevalence of age-related diseases. Founded in 2019, MAC brings together researchers from various disciplines and institutions across the Midwestern United States to foster interdisciplinary geroscience research. This report summarizes the highlights of the Fourth Annual Symposium of MAC, which was held at Iowa State University in May 2023. The symposium featured presentations on a wide array of topics, including studies on slow-aging animals, cellular senescence and senotherapeutics, the role of the immune system in aging, metabolic changes in aging, neuronal health in aging, and biomarkers for measuring the aging process. Speakers shared findings from studies involving a variety of animals, ranging from commonly used species such as mice, rats, worms, yeast, and fruit flies, to less-common ones like naked mole-rats, painted turtles, and rotifers. MAC continues to emphasize the importance of supporting emerging researchers and fostering a collaborative environment, positioning itself as a leader in aging research. This symposium not only showcased the current state of aging biology research but also highlighted the consortium’s role in training the next generation of scientists dedicated to improving the healthspan and well-being of the aging population.
791 Immunological correlates of response to vismodegib and PD-1 blockade in an autochthonous model of basal cell nevus (Gorlin-Goltz) syndrome
Ager, Casey R. , Zhu, Yucui, Chen, Dana, Athar, Mohammed, Izar, Benjamin , Bickers, David R., Jugler, Collin , Chen, Dana, Kim, Arianna L.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A896-A896

10.1136/jitc-2024-sitc2024.0791 Get It

659 A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Maziarz, Richard T, Yuan, Yuan , Krishnamurthy, Anuradha , Isaacs, James , Cairo, Mitchell S. , Cao, Felicia , Advani, Pooja , Locke, Kenneth W., WETZEL, J. M., Klichinsky, Michael , Condamine, Thomas , Sohal, Davendra , Abdou, Yara George , Pohlmann, Paula R. , Maziarz, Richard Thomas , Murthy, Hemant S. , Reiss, Kim A. , He, Aiwu Ruth , Blumenthal, Daniel J. , Locke, Kenneth, Wetzel, Jeanette, Kennedy, Eugene Paul

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A756-A756

10.1136/jitc-2024-sitc2024.0659 Get It

636 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Uboha, Nataliya V. , Chaves, Jorge, Chen, Christopher T. , Powderly, John D. , Zhaohui, Jin, Alistar, Angela , Gabrail, Nashat , Agensky, Laura, Goel, Apollina, Margossian, Steven, Levisetti, Matteo, Quayle, Steve, Kim, Dae Won , Alese, Olatunji B. , Saenger, Yvonne M. , Zheng, Lei , Fu, Siqing , Gong, Jun , Zhaohui, Jin, Bekaii‐Saab, Tanios , Selfridge, Jennifer Eva

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A730-A730

10.1136/jitc-2024-sitc2024.0636 Get It

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Ahn, Daniel H. , Ridinger, Maya , Cannon, Timothy Lewis , Mendelsohn, Lawrence, Starr, Jason S. , Hubbard, Joleen M. , Kasi, Anup , Barzi, Afsaneh , Samuëlsz, Errin , Karki, Anju , Subramanian, Ramanand A. , Yemane, Divora, Kim, Roy , Wu, Chu-Chiao , Croucher, Peter J.P. , Smeal, Tod , Kabbinavar, Fairooz F. , Lenz, Heinz‐Josef , Cannon, Timothy L , Hubbard, Joleen

Mayo Clinic

Journal of Clinical Oncology | October 30, 2024 | Volume: 43 | Issue: 7 | Pages: 840-851

10.1200/jco-24-01266 | PMID 39475591 Get It

PURPOSE This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the second-line treatment of KRAS -mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS This multicenter, open-label, single-arm study enrolled patients with KRAS -mutated mCRC previously treated with oxaliplatin and fluorouracil with or without bevacizumab. Patients received onvansertib (15 mg/m 2 once daily on days 1-5 and 15-19 of a 28-day cycle) and FOLFIRI + bevacizumab (days 1 and 15). The primary end point was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), duration of response (DOR), and tolerability. Translational and preclinical studies were conducted in KRAS -mutant CRC. RESULTS Among the 53 patients treated, the confirmed ORR was 26.4% (95% CI, 15.3 to 40.3). The median DOR was 11.7 months (95% CI, 9.4 to not reached). Grade 3/4 adverse events were reported in 62% of patients. A post hoc analysis revealed that patients with no prior bevacizumab treatment had a significantly higher ORR and longer PFS compared with patients with prior bevacizumab treatment: ORR of 76.9% versus 10.0% (odds ratio of 30.0, P < .001) and median PFS of 14.9 months versus 6.6 months (hazard ratio of 0.16, P < .001). Our translational findings support that prior bevacizumab exposure contributes to onvansertib resistance. Preclinically, we showed that onvansertib inhibited the hypoxia pathway and exhibited robust antitumor activity in combination with bevacizumab through the inhibition of angiogenesis. CONCLUSION Onvansertib in combination with FOLFIRI + bevacizumab showed significant activity in the second-line treatment of patients with KRAS -mutant mCRC, particularly in patients with no prior bevacizumab treatment. These findings led to the evaluation of the combination in the first-line setting (ClinicalTrails.gov identifier: NCT06106308 ).
Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.
Orme, Jacob J. , Lingamaneni, Prashanth, Lavoie, Roxane R. , Hirdler, Jacob, Bering, Elizabeth A., Gicobi, Joanina K. , Hsu, Michelle A. , Dale, Heather, Kottschade, Lisa A. , Block, Matthew S. , Markovic, Svetomir, Olivier, Ken, Owen, Dawn , Dronca, Roxana , Packard, Annie T. , Zhang, Henan , Kim, Yohan , Dorr, Maddy, Dizona, Paul, Hirdler, Jacob B. , Hsu, Michelle, Dale, Heather, Childs, Daniel S. , McWilliams, Robert R. , Mansfield, Aaron S. , Markovic, Svetomir N. , Lester, Scott C. , Daniel, J. , Dong, Haidong , Lucien, Fabrice , Winters, Jeffrey L. , Park, Sean S.

Mayo Clinic

No container title available | October 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4542220/v1 Get It

Abstract Introduction: Immune checkpoint inhibitors (ICI) are an essential systemic therapy for advanced melanoma. However, most melanomas develop resistance to ICI. Tumor-derived soluble PD-L1 (sPD-L1) and other soluble immunosuppressive factors drive checkpoint inhibitor resistance and correlate with inferior survival. We previously showed that therapeutic plasma exchange (TPE) removes sPD-L1 from circulation. Thus, we hypothesized that TPE-mediated removal of sPD-L1 and other immunosuppressive factors could overcome immunotherapy resistance in refractory melanoma. Methods: In this clinical trial (NCT04581382), we prospectively enrolled eighteen (18) patients with widely metastatic melanoma with progression despite anti-PD-1 ICI and elevated sPD-L1 by ELISA (≥1.7ng/mL). Each patient received radiotherapy to between one and three metastatic lesions (at least two unirradiated lesions) followed by three TPE sessions on consecutive days and re-challenge with checkpoint inhibitor. The primary safety and efficacy endpoints of the study were adverse events (AEs) and sPD-L1 reduction by TPE, respectively. Secondary endpoints included RECIST-based response in unirradiated lesions and overall survival. Correlative studies included kinetics of sPD-L1 and soluble immonsuppressive factors and dynamics of peripheral immune cell phenotypes. Results: Mean age was 62 (SD 13) and seven of eighteen (39%) were female. Mean baseline sPD-L1 was 26.31 ng/mL (40.01). The treatment was well-tolerated with one (6%) patient with grade 3 and 4 adverse events from a central line infection after TPE. Levels of sPD-L1 were significantly reduced by TPE (mean 80.2% reduction, p<0.0001). Two patients (11.1%) experienced complete response (CR), one (5.6%) partial response, three (16.7%) stable disease, and 12 (66.7%) progressive disease. In one case, immunotherapy was discontinued after two years due to no detectable lesions. Changes in tumor-reactive (TTR) GZMB+/CX3CR1+/CD11ahigh and other peripheral immune cell populations predicted overall survival in this cohort. In addition to sPD-L1, other soluble mediators of ICI resistance were also reduced by TPE and predicted overall survival in this cohort. Summary/Conclusion: sPD-L1 and other soluble immunoregulatory signaling molecules are important mediators of ICI resistance. SBRT and TPE can resensitize ICI-refractory melanoma by removing these factors. Patients with persistently elevated or rapid rebound of sPD-L1 following TPE experienced poor response and overall survival. Serial monitoring of sPD-L1 may predict response to ICI and multiple courses of TPE may be necessary. Our findings may apply in other ICI-resistant cancers with elevated sPD-L1. ClinicalTrials.gov registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).